(STXS) Stereotaxis, Inc. Business Model Canvas Research

Stereotaxis used sales agents in selected markets to help commercialize its robotic interventional systems and reach interventional laboratory buyers faster. This fits its mixed go-to-market model, which combines direct selling with local partners.

• Supports commercialization in selected markets
• Connects with lab buyers directly
• Backs a hybrid sales model

Hospitals and interventional labs are the deployment gate for Stereotaxis, Inc. systems, because they host the robotic navigation, imaging, and data workflows that drive daily use. Their adoption expands the installed base and supports recurring system utilization across electrophysiology and other catheter procedures.

• Deployment site for robotic systems
• Enables imaging and data capture
• Drives installed-base growth

Stereotaxis, Inc. builds disposable catheter and accessory products around QuikCAS, Vdrive parts, and RMT catheter lines, so each case can drive repeat consumable demand. The strategy supports recurring procedural use and expands the consumables mix across the installed base of robotic systems.

• 3 product lines: QuikCAS, Vdrive, RMT
• Repeat use supports recurring revenue
• Broader consumables pull from installed base

Stereotaxis, Inc.'s Odyssey real-time information platform manages, records, and securely shares procedural data, so interventional labs can keep workflows aligned during robotic cases. The system supports case tracking, documentation, and review inside the lab, which is central to procedural control and data continuity.

• Real-time procedural data control
• Secure sharing across lab teams
• Workflow integration for interventional labs

Stereotaxis, Inc. uses a commercial network of direct sales staff, distributors, and sales agents to sell its robotic surgery systems in the United States and abroad. This channel mix helps reach specialized hospital buyers and supports a global installed base of over 400 systems.

• Direct sales covers core domestic accounts
• Distributors extend international reach
• Sales agents help access niche buyers

Founded in 1990 and based in Saint Louis, Missouri, Stereotaxis, Inc. uses its headquarters as the core for development and commercialization. That base anchors U.S. operations and supports global market execution.

• Founded: 1990

• Headquarters: Saint Louis, Missouri

• Role: development and commercialization hub

• Coverage: U.S. and global markets

Imaging Mod S combines five core components—X-ray, C-arm, powered table, motorized boom, and HD monitors—into one robotic interventional room, so Stereotaxis, Inc. can support a tighter, more efficient procedure flow. It is built for robotic interventional operating rooms and creates a more integrated procedural environment for complex cases.

• Five-in-one room integration
• Built for robotic workflows
• Supports cleaner procedure flow

Stereotaxis, Inc. sells steerable tip diagnostic and ablation catheters, Vdrive items, and related disposables, so each installed system can keep generating procedure-linked revenue. That broad accessory base expands use across workflows and supports repeat clinical demand after the initial capital sale.

• Recurring use after system placement
• Catheters, Vdrive, and disposables
• Broader workflow coverage

Clinical adoption support is central for Stereotaxis, Inc. because robotic EP systems need hands-on training, case planning, and workflow fit before labs can use them well. In 2025, Stereotaxis reported revenue of about $28 million, showing that selling the platform depends not just on hardware, but on helping hospitals move complex ablation cases into routine use.

This relationship is strongest in advanced electrophysiology, where operator learning curves and lab integration can slow uptake, so support teams stay close through onboarding and case guidance.

• Training drives platform use
• Workflow fit supports adoption
• Complex EP cases need guidance

Disposable catheters and accessories turn Stereotaxis, Inc. from a one-time equipment seller into a repeat-supply partner. Customers come back for QuikCAS, Vdrive items, and catheter supplies after the initial system sale, which keeps commercial ties active across procedures and supports recurring revenue.

• Repeat use drives ongoing orders.
• QuikCAS and Vdrive are replenished.
• Consumables extend customer lifetime value.

Stereotaxis commercializes its robotic navigation products outside the United States, so international channel support is a key part of reaching hospitals in more than 70 countries and widening the addressable market beyond the U.S. This matters because overseas sales can scale demand for systems, catheters, and service without relying on one market.

• Supports sales beyond the U.S.
• Reaches 70+ countries
• Expands addressable market

Interventional laboratory deployment places Stereotaxis systems directly in cath labs and robotic operating rooms, so installation is part of the capital-equipment sale. In FY2025, that channel supported procedure-linked use by turning each system sale into an active workflow touchpoint, not just a one-time install.

• Direct placement in cath labs
• Includes install and setup
• Links sales to procedures

Stereotaxis, Inc. serves domestic U.S. customers from its U.S. base, mainly hospitals, labs, and procedural centers that use its robotic magnetic navigation systems. These buyers drive core commercial traction in the U.S. market, where the company’s installed base supports recurring clinical use and system placements.

• Hospitals and labs
• Procedural centers
• U.S. commercial traction

International customers extend Stereotaxis, Inc. beyond the U.S., with overseas demand reached through distributors and sales agents. That model keeps fixed selling costs lighter than a direct field force and helps the Company grow in more hospitals and markets at once.

• Overseas demand broadens growth
• Distributors and agents support reach
• Less dependence on U.S. sales

Clinical support and training raise Stereotaxis, Inc. costs because its robotic interventional systems need onboarding, case support, and workflow coaching before hospitals can use them at scale. This service layer helps adoption, but it also adds recurring labor and travel expense on top of product sales.

• Onboarding drives system adoption
• Case support lowers user friction
• Training adds service operating cost

Alliance work and Saint Louis headquarters activity add fixed overhead to Stereotaxis, Inc. Strategic collaboration support, corporate staff, and general administrative costs sit in this cost base, so operating leverage stays sensitive to revenue growth. The Saint Louis base houses core corporate functions.

• Strategic collaboration overhead
• Saint Louis corporate functions
• General administrative expense

In 2025 filings, this structure mainly reflects people, office, and deal-support costs.

Stereotaxis, Inc.'s disposable catheter and accessory sales, including QuikCAS, Vdrive items, and RMT catheters, create repeat purchase revenue because each procedure consumes new product. In 2024, Stereotaxis reported $28.1 million in total revenue, and these consumables are the core recurring driver behind that base.

• QuikCAS, Vdrive, and RMT are procedural consumables.
• Each case can trigger repeat sales.
• 2024 total revenue: $28.1 million.

Stereotaxis, Inc. also sells through distributors and sales agents, which supports both domestic and international bookings and extends reach into markets the direct team cannot cover alone. This partner-led model helps widen access to its robotic surgery systems and keeps the sales funnel active across regions.

• Broader market reach through local partners
• Supports domestic and international bookings
• Helps scale without heavy direct-sales costs